Corcept Therapeutics announces the Grace Study for Cushing

Written on .


Corcept colorlogo jpegThe purpose of the Grace Study is to evaluate the effectiveness (benefits) and safety (side effects) of an investigational study medicine, relacorilant, in treating participants with endogenous Cushing syndrome, also known as hypercortisolism. All eligible participants will receive the investigational study medicine.


To download the PDF Brochure       CLICK HERE.